UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~November~~May 1626, ~~2022~~2023

Date of Report (Date of earliest event reported)

Q BioMed Inc.

(Exact name of registrant as specified in its charter)

Nevada	000-55535	46-4013793
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Ortoli Rosenstadt LLP

366 Madison Avenue, 3^rd Floor

New York, NY

10017

(Address of principal executive offices)

(Zip Code)

(212) 588-0022

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 38.0201 ~~Unregistered~~Other ~~Sales of Equity Securities~~Events

On ~~November~~May 1826, ~~2022~~2023, we ~~issued~~filed ~~1,000,000~~an ~~Series~~annual Creport ~~Preferred~~on ~~Shares~~Form ~~(as~~10-K. ~~defined~~We ~~below)~~note inthat ~~exchange~~that ~~for~~annual report does not meet fully the ~~settlement~~requirements of ~~$50~~annual reports as required by Form 10-K. Particularly,~~000~~ we note that the financial statements included in ~~amounts~~that ~~due~~annual report have not been audited and no audit report regarding such financial statements was included therein. The financial statements included in the annual report are not the type of financial statement that an investor would expect to ~~our~~see ~~directors~~from a company that has had its financial statements audited by an independent accounting firm per the Securities Exchange Act of 1934, as amended, and/ the rules and regulations promulgated thereunder. The recently filed annual report is unaudited, incomplete and should not be relied upon as accurate, timely or ~~officers~~fit for any purpose. Although the Company intends to amend that annual report as soon as practicable and invites any inquiries to be directed to Company management, it may not be able to ever amend that annual report.

The securities mentioned above were issued, or will be issued, in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Act”), and Rule 506 of Regulation D promulgated under the Act. This transaction qualified for exemption from registration because among other things, the transaction did not involve a public offering, the investor was an accredited investor and/or qualified institutional buyer, the investor had access to information about our company and its investment, the investor took the securities for investment and not resale, and we took appropriate measures to restrict the transfer of the securities.

Item 3.03 Material Modification to Rights of Security Holders.

The information set forth in Item 1.01 hereof is incorporated by reference into this Item 3.03.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Our Articles of Incorporation, as amended, authorize us to issue up to 100,000,000 million shares of preferred stock with the consent of our Board of Directors and without any further consent from our holders of capital stock. On November 16, 2022:

· our Board of Directors authorized the creation of up to 1,000,000 shares of Series C Convertible Preferred Stock (the “Series C Preferred Shares”)

· we filed a Certificate of Designations with the Secretary of Nevada creating such Series C Preferred Shares

The foregoing is only a summary of the Certificate of Designations, which is filed as an exhibit hereto, so that you may more fully understand the terms the Series C Preferred Shares.

Liquidation. The Series C Preferred Shares have a liquidation preference that is junior to our Series A convertible preferred stock, Series B preferred stock and our common stock. The holders of the Series A Preferred Shares shall be entitled to receive a payment in an amount that is equal to $0.05 per share plus any dividends that are due on such share (the “Liquidation Value”).

Dividends. The holders of the Series C Preferred Shares shall be entitled to receive, when, if and as declared by our board of directors, out of funds legally available therefor, any dividends or other distributions that we declare on the common stock, $0.001 par value per share, of the Corporation (the “Common Stock”) (other than dividends payable solely in additional shares of Common Stock).

Voting. The Series C Preferred Shares shall vote together with the Common Stock, and each Series C Preferred Share shall have two hundred (200) votes for each vote held by a share of Common Stock.

Forced conversion. The Series C Preferred Shares shall convert into shares of Common Stock on the earlier of:

· the five-year anniversary of the filing of this Certificate of Designations;

· the date on which any of the Company’s securities is listed on a National Securities Exchange; and

· a date agreed upon by the majority of the Series C Preferred Share voting together as a class (including by written consent).

The number of shares of Common Stock to be issued upon conversion shall equal the aggregate amount of the Liquidation Value being converted divided by the higher of (a) $0.0209 (110% of the volume weighted average price of the Common Stock on the trading day immediately prior to the filing of the certificate of designations for the Series C Preferred Shares) or (b) 110% of (i) the initial public offering price if such conversion occurs in connection with a listing on a national securities exchange, (ii) the volume weighted average price of the common stock on the trading day immediately prior to such conversion as reported by Bloomberg, (iii) in the event Bloomberg does not report such information, the closing bid price of the Common Stock on the national securities exchange or, if none, over the counter bulletin board containing such information or (iv) if the data in (i), (ii) and (iii) are not available, a good-faith estimate by the majority of the board of directors of the market value of the Common Stock.

Item 9.01

Financial Statements and Exhibits.

Exhibits.

3.1	Certificate of Designations for Series C Convertible Preferred Stock filed on November 16, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Q BioMed Inc.
Date: November 18, 2022	By:	/s/ Denis Corin
Date: May 26, 2023	By:	/s/ Denis Corin
	Name:	Denis Corin
	Title:	President and Chief Executive Officer

Filing Compare · Q BioMed Inc.